BGI
B Group Inc Portfolio holdings
AUM
$116M
This Quarter Return
+10.91%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$116M
AUM Growth
+$116M
(+0.61%)
Cap. Flow
-$7.83M
Cap. Flow
% of AUM
-6.76%
Top 10 Holdings %
Top 10 Hldgs %
93.43%
Holding
19
New
–
Increased
8
Reduced
3
Closed
2
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$2.27M |
| 2 |
Taysha Gene Therapies
TSHA
|
$1.26M |
| 3 |
Praxis Precision Medicines
PRAX
|
$673K |
| 4 |
Aura Biosciences
AURA
|
$626K |
| 5 |
Sight Sciences
SGHT
|
$398K |
Top Sells
| 1 |
Insmed
INSM
|
$10.8M |
| 2 |
BioNTech
BNTX
|
$1.37M |
| 3 |
89bio
ETNB
|
$695K |
| 4 |
Akero Therapeutics
AKRO
|
$536K |
| 5 |
Assembly Biosciences
ASMB
|
$193K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$4.12B
| $42.2M | 32.48% |
2,317,542
| – | – |
|
|
2
Insmed
INSM
$28.8B
| $15.6M | 12.01% |
155,000
-107,500
| -41% | -$10.8M |
|
3
Zai Lab
ZLAB
$3.68B
| $14M | 10.77% |
400,000
| – | – |
|
|
4
Akero Therapeutics
AKRO
$3.74B
| $12.4M | 9.55% |
232,446
-10,054
| -4% | -$536K |
|
|
CLLS
5
Cellectis
CLLS
$258M
| $4.97M | 3.82% |
3,256,501
| – | – |
|
|
6
Taysha Gene Therapies
TSHA
$797M
| $4.16M | 3.2% |
1,800,556
+545,000
| +43% | +$1.26M |
|
|
7
Ultragenyx Pharmaceutical
RARE
$2.89B
| $4M | 3.08% |
110,000
+62,500
| +132% | +$2.27M |
|
|
8
Sight Sciences
SGHT
$213M
| $3.84M | 2.96% |
930,000
+96,400
| +12% | +$398K |
|
|
9
Aura Biosciences
AURA
$389M
| $3.58M | 2.76% |
572,576
+100,000
| +21% | +$626K |
|
|
10
Assembly Biosciences
ASMB
$190M
| $3.43M | 2.64% |
189,350
-10,650
| -5% | -$193K |
|
11
Iovance Biotherapeutics
IOVA
$807M
| $2.58M | 1.99% |
1,500,000
| – | – |
|
12
Apogee Therapeutics
APGE
$2.17B
| $1.52M | 1.17% |
35,000
+5,000
| +17% | +$217K |
|
|
13
Praxis Precision Medicines
PRAX
$958M
| $1.47M | 1.13% |
35,000
+16,000
| +84% | +$673K |
|
14
Spyre Therapeutics
SYRE
$996M
| $1.2M | 0.92% |
80,000
+10,000
| +14% | +$150K |
|
|
ORKA
15
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $841K | 0.65% |
75,000
+16,785
| +29% | +$188K |
|
|
16
BioNTech
BNTX
$24B
| – | – |
-15,000
| Closed | -$1.37M |
|
17
Corvus Pharmaceuticals
CRVS
$428M
| – | – |
0
| – | – |
|
|
18
89bio
ETNB
$1.34B
| – | – |
-95,623
| Closed | -$695K |
|
19
Eli Lilly
LLY
$657B
| – | – |
0
| – | – |
|